Clinical trials: Primary Focal Segmental Glomerulosclerosis
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid…
- Trial name
- NCT05441826
- Testing
- VB119
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tenet Medicines
Focal Segmental Glomerulosclerosis
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
- Trial name
- DUPLEX (NCT03493685)
- Testing
- sparsentan, Irbesartan
- Where
- 226 sites in United States, Argentina and 20 more
- Volunteers
- 371 people
- Sponsor
- Travere Therapeutics, Inc.
Primary Focal Segmental Glomerulosclerosis
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.
- Trial name
- NCT03422510
- Testing
- CXA-10
- Where
- 24 sites in United States
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Trial name
- RESULT (NCT06500702)
- Testing
- frexalimab, brivekimig, rilzabrutinib
- Where
- 79 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Primary Focal Segmental Glomerulosclerosis
Obinutuzumab in Primary FSGS
The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
- Trial name
- NCT04983888
- Testing
- Obinutuzumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 316 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far.
- Trial name
- NCT04369183
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Istanbul University
Kidney Diseases
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring.
- Trial name
- NCT01155141
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Primary Focal Segmental Glomerulosclerosis
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
The primary objectives of this trial are as follows: to compare the achievement of a partial remission (PR) or complete remission (CR) in urinary protein: creatinine ratio (Up/c ratio) in patients treated with fresolimumab versus…
- Trial name
- FSGS (NCT01665391)
- Testing
- fresolimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Proteinuria, Focal Segmental Glomerulosclerosis
Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of prednisone and tripterygium wilfordii in treated Focal Segmental Glomerulosclerosis (FSGS).
- Trial name
- NCT00801463
- Testing
- tripterygium wilfordii (TW)
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Nanjing University School of Medicine
Focal Glomerulosclerosis
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.
- Trial name
- NCT00302536
- Testing
- Tacrolimus
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Focal Segmental Glomerulosclerosis
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS).
- Trial name
- NCT02382874
- Testing
- Intravenous injection
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Primary Membranous Nephropathy, Minimal Change Disease
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease.
- Conditions
- Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT07861113
- Testing
- Sibeprenlimab
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Focal Segmental Glomerulosclerosis
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal…
- Trial name
- FSGSALLAGE (NCT04065438)
- Testing
- LIPOSORBER® LA-15
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Kaneka Medical America LLC